White House announces MFN agreement with drug manufacturer Regeneron

The administration Apri 23 reached a most-favored-nation drug pricing agreement with Regeneron, the maker of the popular cholesterol medicine Praluent. This is the 17th such agreement by a drug manufacturer with the Trump administration, and it ensures Regeneron's prices are in line with the lowest prices paid by other developed nations. The agreement also ensures that Regeneron's novel gene therapy for rare genetic deafness, Otarmeni, will be made available to U.S. patients at no cost.